Review

Amyotrophic Lateral Sclerosis

JAMA 10.1001/jama.2026.6385

May 11, 2026 at 11:05 AM EDT

Read the full article

Amyotrophic lateral sclerosis is a progressive and fatal neurodegenerative disorder of upper and lower motor neurons. No curative therapies exist. Two oral medications, riluzole and edaravone, are approved by the FDA and modestly decrease disease progression in sporadic ALS. Tofersen, an intrathecally administered gene-based therapy, is also FDA approved and slows disease progression in patients with pathogenic gene variants.

Corresponding Author: John Ravits, MD, Altman Clinical Translational Institute, University of California, San Diego, 9452 Medical Center Dr, Ste 2W-108, La Jolla, CA 92037 (jravits@health.ucsd.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks